• Research Grade Lpathomab
1 1

AntibodySystem

DVV02803-1MG

Research Grade Motavizumab

Research Grade Motavizumab

$318.00 USD
$318.00 USD
Sale Sold out
Shipping calculated at checkout.
Size

Catalog No.: DVV02803

Catalog No. DVV02803
Product name Research Grade Motavizumab
Size 1 mg; 5 mg; 25 mg
Host species Humanized
Species reactivity HRSV-A
Form Liquid
Storage buffer 0.01M PBS, pH 7.4.
Purity >95% as determined by SDS-PAGE.
Clonality Monoclonal
Isotype IgG1, kappa
Applications Research Grade Biosimilar
Target F, Fusion glycoprotein F0, Fusion glycoprotein F2, p27, Intervening segment, Pep27, Peptide 27, Fusion glycoprotein F1
Purification Protein A/G purified from cell culture supernatant.
Endotoxin level Please contact with the lab for this information.
Expression system Mammalian Cells
Accession P03420
Stability and Storage Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names MEDI-524,NUMAX, NISTmAb, CR9503, CAS: 677010-34-3
Clone ID Motavizumab
Note For research use only. Not suitable for clinical or therapeutic use.
Description Motavizumab (MEDI-524, NUMAX, NISTmAb) is a second generation monoclonal antibody (mAb) derived from palivizumab (Synagis) using affinity maturation techniques. Motavizumab is currently undergoing US Food and Drug Administration review as a treatment for respiratory syncytial virus (RSV) prophylaxis. It has been evaluated in large-scale clinical studies, and has demonstrated efficacy in reducing the disease burden of RSV in high-risk infant populations.Motavizumab (MEDI-524, NUMAX, NISTmAb) has higher affinity and a longer half-life, was effective in reducing RSV hospitalization in high-risk full-term infants in the US, but was not licensed due to safety concerns (allergic reactions) .
View full details